

Clarksville Montgomery County Employees
Insurance Trust Meeting

October 23, 2024

The meeting of the Clarksville Montgomery County employees Trust was held on Wednesday, October 23, 2024 at 4:15 p.m. in the District Meeting Room.

Members in attendance were Melissa Izatt, Jeff Taylor, Tommy Butler, Teresa Cottrell, Bart Dixon, Gene Fish, Heather Fleming, Shannon Hadley, Mark Krussow, Robbie McCord, Cassandra Osborne, Lindsey Rittenberry, John Smith, and Cassie Wheeler. Also in attendance were Chris Fessenden and Kim Moss of Fessenden Consulting Group, Carol Joiner CMCSS General Counsel, Jessica Whitfield CMCSS Business Affairs, Tracy Boisseau, Christy Rowland, Stacey Smith, and Amy Wigington CMCSS Benefits Office, Lauren Richmond CMCSS Safety and Health, and Tiffany Maxwell and Sharla Smith Onsite Medical Clinic.

Melissa Izatt called the meeting to order at 4:15 p.m. A quorum was established.

Minutes from the September 30, 2024 meeting were reviewed. Motion to accept the minutes was made by Cassandra Osborne. Gene Fish seconded. All Trust members verbally voted yes. Motion carries.

Chris Fessenden provided the Trust members with the September 2024 Medical Plan Experience Report along with a Medical/Rx Cost Summary. The medical loss ratio for September was 107.9%. The year to date medical loss ratio was 107.9%. The plan is in good standing.

Jeff Taylor, CMCSS Chief Financial Officer, presented the financial statements for July 2024. The total liabilities and fund balance is \$26,977,397.56. Trustee's report balance \$27,004,965.96. John Smith made a motion to accept the financial statements as presented. Bart Dixon seconded. All Trust members verbally voted yes. Motion carries.

Tommy Butler presented the 2024 Insurance Trust Financial Snapshot.

Premium Reconciliation Update (County Member). Melissa Izatt stated that the county member previously mentioned in the September 30, 2024 meeting has paid their missed insurance premium.

Gene/Cell Therapy Presentation. Kelly Metcalf and Katie Brown with EpiphanyRx joined the meeting via zoom. Kelly Metcalf, MS, Sr. Client Services Executive, presented the EpiphanyRx overview. EpiphanyRx was established in 2016 and acquired by Navitus in 2021. EpiphanyRx offers transparency, cost-effective formulary, drug coverage reviews, and innovative programs.

Katie Brown, PharmD, MBA, Sr. Clinical Account Executive, presented the cell and gene therapy discussion. Gene therapy modifies a person's genes to treat disease. Diseases treated by gene and cell therapy fall into two categories: Rare and ultra-rare conditions. Rare disease affects fewer than 200,000 people in the US to include spinal muscular atrophy, severe Hemophilia A and B, Retinal dystrophy, and Duchenne muscular dystrophy. Ultra rare disease affects fewer than 7,000 people in the US to include Beta-thalassemia, Adrenoleukodystrophy, and Dystrophic epidermolysis bullosa. Gene therapy modifies a person's genes to treat disease by either replacing, inactivating, or introducing a new or modified gene into the body. Cell therapy is the transfer of a specific cell type, or types, into a patient to treat or prevent disease. Cells can come from the person's own body or a compatible donor. Therapeutic results of gene and cell therapy include small studies, lack long term results, offers benefits but not necessarily curative over a lifetime, and concerns regarding serious adverse events. The annual cost for gene therapy ranges from 1 million - 3.5 million and \$400,000 - \$800,000 for cell therapy. Most medications are given one time through IV infusion. Other considerations are long term effects and funding options. Will gene/cell therapy reduce the need for other medications? How long will gene/cell therapy last? Will there need to be a re-treatment and is that even possible? Patient assistance via the manufacturer is a funding option for excluded drugs.

The next meeting will be held Tuesday, January 14, 2025 at 4:15 p.m. in the Lecture Hall.

The meeting was adjourned at 4:57 p.m.